Reducing Febrile Neutropenia in iBC-NHL Patients
Researchers investigated the effectiveness of primary anti-infectious prophylaxis in reducing febrile neutropenia and treatment interruptions in older patients with indolent B-cell non-Hodgkin lymphomas (iBC-NHLs) receiving bendamustine-rituximab (BR) treatment.
Real-world experience in clinical practice shows a gradual transition from multiagent chemo-immunotherapy (rituximab, cyclophosphamide, doxorubicin, oncovin, prednisone [R-CHOP]) to [BR] for frontline treatment of [iBC-NHL]
Vigorous primary anti-infectious prophylaxis significantly reduces the incidence of febrile neutropenia and treatment interruptions in these patients, according to research published in Supportive Care in Cancer.
Author's summary: Prophylaxis reduces febrile neutropenia in iBC-NHL patients.
More News
- ‘My heart is broken’: Domestic worker mourns sister who died in Hong Kong fire
- Etihad to welcome over 2 million December passengers as winter travel demand soars
- Official UFC 324 Main Card Bout Order : r/MMA
- Etihad Airways Adds New 8-Hour Airbus A321LR Flights To Europe
- November Routes Roundup: Etihad Airways Launches Abu Dhabi–Tokyo A380 Service
- 01 – Air Libre - Podcasts
- ‘Reviewing it’: Hegseth on releasing video of Caribbean strike; survivors died on alleged drug boat
- 41 People Who Almost Died Are Sharing How They Barely Survived
- [Les structures causales en français : exprimer la cause]
- Etihad’s A380 to Tokyo in Summer 2026